Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways
20 May 2025 (09:45 - 09:53)
Organised by: 
About the speaker
National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)
6 More presentations in this session
Doctor M. Laufer-Perl (Tel Aviv, IL)
Doctor M. Gvili Perelman (Tel Aviv, IL)
Access the full session
The Event
Heart Failure 2025
20 May 2025
09:45 CET
You may be interested in
Congress Presentation
